(Q24247441)

1

object named as

Angela C Webster

0 references

author name string

Elliott Geoffrey Playford

2

0 references

Gail Y Higgins

3

0 references

Jeremy R Chapman

Cochrane Database of Systematic Reviews

4

0 references

publication date

26 January 2004

0 references

published in

0 references

cites work

Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Results of renal transplantation with different immunosuppressive regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Basiliximab can be administered safely and effectively in a single dose on day 1 postrenal transplantation in patients receiving triple therapy with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Economic analysis of basiliximab in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Preliminary results of a prospective randomized study of basiliximab in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Role of anti-interleukin-2 receptor antibodies in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Balancing benefits and harms in health care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Immunosuppressive strategies in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Strategies to improve long-term outcomes after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Tailoring immunosuppressive therapy for renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Screening for basiliximab exposure-response relationships in renal allotransplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Renal transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. II. Results after a second kidney transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021

Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB2

7 January 2021